Company Overview of Xigen SA
Xigen SA, a biopharmaceutical company, develops therapeutics to inhibit intracellular protein-protein interactions for the treatment of various diseases in the areas of inflammation, central nervous system, oncology, and virology, as well as cancers. Its products include XG-102, a non-ATP competitive peptide based inhibitor of c-jun N-terminal kinase (JNK) that is an intracellular therapeutic target; and XG-102 (AM-111) for acute sensorineural hearing loss. The company was founded in 2002 and is based in Lausanne, Switzerland.
17, rue des Terreaux
Founded in 2002
41 21 321 10 80
41 21 321 10 81
Key Executives for Xigen SA
Similar Private Companies By Industry
|AB2 Bio Ltd.||Europe|
|ADC Products Switzerland SARL||Europe|
|ADC Therapeutics SA||Europe|
|AlloCyte Pharmaceuticals AG||Europe|
|Amal Therapeutics SA||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Xigen SA, please visit www.xigenpharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.